Company* (Country, Symbol) | Company* (Country, Symbol) | Type/Product Area | Terms/Details (Month) |
Abgenix Inc. (ABGX) | SangStat Medical Corp. (SANG) | Global co-development supply and license agreement for ABX-CBL | SangStat will have an exclusive worldwide license for the marketing and sale of ABX-CBL and, subject to terms and conditions, the right to commercialize other anti-CD147 antibodies; Abgenix will manufacture ABX-CBL; SangStat will make an initial license fee payment and additional milestone payments; development costs and potential profits will be shared equally (8/8) |
Access Pharmaceuticals Inc. (AMEX:AKC) | Laboratorios Dr.Esteve SA and Isdin SA (Spain) | Licensing agreement for OraRinse, amlexanox cream and amlexanox gel | Access signed letters of intent to exclusively license the products to Esteve and Isdin for Portugal, Spain and Greece; Esteve and Isdin will make up-front licensing payments and milestone payments and Access will receive a percentage of product sales for supplying the product; Esteve will make an equity investment in Access and provide funding for European clinical research (8/29) |
Adherex Technologies Inc. * (Canada) | BioChem Pharma Inc. (BCHE) | Collaboration to develop Exherin, Adherex's new compound for cancer | Both companies will participate in research and development activities; BioChem may pay Adherex up to US$25.5M in the form of milestone payments and an equity stake, in addition to sales revenues (8/22) |
Aeson Inc. Therapeutics * | Hollis-Eden Pharmaceuticals Inc. (HEPH) | Exclusive worldwide sublicense to three additional issued patents in the area of adrenal steroids | Hollis-Eden is exchanging $2M in cash and 208,681 shares for a 21% equity interest in Aeson (10/12) |
Affymetrix Inc. (AFFX) | Decode Genetics Inc.(Iceland; DCGN) | Agreement for BiotechAccess program | Decode will gain broad access to Affymetrix's standard GeneChip arrays, instrumentation and software to monitor gene expression (8/10) |
Agilent Technologies Inc. (NYSE:A) | DiaDexus Inc.* | Agreement for gene expression system technology | Agreement will allow diaDexus to obtain access to Agilent's customizable microarray technology for research into the molecular basis for cancer and other diseases; financial details were ND (10/23) |
Agilent Technologies Inc. (NYSE:A) | Exelixis Inc. (EXEL) | Supply agreement for customizable DNA microarrays | Agilent agreed to supply customizable DNA microarrays to Exelixis, which will use the platform for expression profiling experiments; financial details were ND (10/12) |
Agilent Technologies Inc. (NYSE:A) | Paradigm Genetics Inc. (PDGM) | Technology access program agreement | Agreement will grant Paradigm early access to Agilent's customizable microarray technology; financial details were ND (10/11) |
AMBI Inc. (AMBI) | Biosynexus Inc.* | Licensing agreement for rights to nisin and lysostaphin anti-bacterial technologies | Biosynexus will pay AMBI $1.4M upfront, up to $14M in milestones, royalties on potential sales, and will grant warrants for the purchase of Biosynexus shares (8/3) |
Amgen Inc. (AMGN) | HealthCite* | Strategic partnership to collaborate on software, technology and web development opportunities | Terms include a $10M direct investment by Amgen in HealthCite (8/3) |
Amylin Pharmaceuticals Inc. (AMLN) | Alkermes Inc. (ALKS) | Completion of the feasibility stage of a collaboration for the development of an injectable long-acting release formulation of AC2993 | Amylin and Alkermes completed the feasibility stage of the collaboration and additional preclinical work has begun to support AC2993 as a treatment for Type II diabetes; Alkermes received a milestone payment (10/17) |
AngioSense Inc.* | Repair Inc.* | Joint collaboration to pursue clinical applications for sustained delivery of fibroblast growth factor to simulate the growth of new blood vessels in diseased hearts |
AngioSense will supply its needle-free, jet-injection delivery system and Repair will provide FGF protein and fibrinogen constructs; financial details were ND (10/19) |
AnVil Informatics Inc.* | PolyGenyx Inc.* | Collaboration on bioinformatics projects | Companies will work jointly on projects related to PolyGenyx's SNP genotyping and haplotyping programs; AnVil will build a database suitable for hosting data from PolyGenyx's laboratory; companies also are in discussion for a longer-term collaboration on data exploration projects (9/5) |
Applied Molecular Evolution Inc. (AMEV) | IDEXX Laboratories Inc. (IDXX) | Non-exclusive sublicense to Applied Molecular's Kauffman patents for directed evolution | Applied Molecular granted a non-exclusive sublicense to IDEXX, which will use the patents to develop diagnostic applications; the patents cover methods of stochastically generating proteins (9/14) |
Ariad Pharmaceuticals Inc. (ARIA) | NsGene AS* (Denmark) | Collaboration to evaluate small-molecule regulated gene and cell therapy products for central for nervous system diseases | Companies will combine the Ariad Regulated Gene Expression Technology with NsGene's neurotrophic factors and technologies for culturing and engineering neural cells; development and commercial terms will be determined following the initial research phase of the collaboration (9/20) |
ArQule Inc. (ARQL) | Genome Therapeutics Corp. (GENE) | Drug discovery collaboration | Arqule will use Parallel Track Drug Discovery program to screen and optimize compounds against anti-infective targets, which Genome derived from its PathoGenome Database; the agreement replaces the 1998 collaboration and includes increased commitment of resources from both companies and joint ownership rights to all lead compounds and commercial outcomes (10/18) |
ArQule Inc. (ARQL) | Nanoscale Combinatorial Synthesis Inc.* | Microchemistry technology evaluation and chemistry services agreement | Nanosyn will perform custom chemical synthesis projects enabling ArQule to evaluate Nanosyn's Accelerated Nanoscale Synthesis Technology System; ArQule will provide funding for a period of up to two years; financial terms were ND (8/17) |
Array BioPharma Inc. (ARRY) | Immunex Corp. (IMNX) | Multi-year agreement providing access to small-molecule libraries | Array will provide Immunex with access to small-molecule libraries for screening against Immunex's high-throughput screening assays; Immunex will gain access to the libraries on a non-exclusive basis; Array retains an exclusive option to enter into a lead-optimization agreement with Immunex to develop leads generated; financial terms were ND (10/3) |
Athersys Inc.* | Molecumetics Ltd. (unit of Tredegar Corp. NYSE:TG) | Development collaboration for small-molecule drugs | Athersys will use its RAGE-VT technology to provide Molecumetics with 12 cell lines expressing validated targets of interest; Molecumetics can access the targets by paying a licensing fee or through a co-development option allowing both companies to co-invest in particular projects and share in downstream value (10/16) |
Antex Biologics Inc. (AMEX:ANX) | Lyotropic Therapeutics LLC* | Collaboration to formulate Antex's antibiotic candidates with Lyotropic's LyoCell drug delivery system |
The preclinical drug candidates are being developed to treat serious infections caused by vancomycin-resistant Enterococci, methicillin-resistant Staphylococcus aureus and other organisms (9/27) |
AutoImmune Inc. (AIMM) | Rycor Technology Investments Corp.* | Exclusive license for Auto-Immune's methods to treat autoimmune diseases | The license agreement covers the development by Rycor of native myelin basic protein peptides for injection to non-mucosal sites for the treatment of multiple sclerosis (8/22) |
AxCell Biosciences Corp. (unit of Cytogen Corp.; CYTO) | Molecular Staging Inc.* | Collaboration to investigate biochips to accelerate mapping of human proteome | The companies initiated a plan to investigate potential synergies between their technologies to map protein pathways more rapidly and efficiently (10/2) |
Axonyx Inc. (AXYX) | Serono SA (Switzerland; NYSE:SRA) | Agreement to acquire exclusive worldwide rights to two of Axonyx's drug platform technologies | Serono is exercising its option to gain exclusive rights to Axonyx's amyloid- and prion-inhibitory peptides, which were subject to the May 1999 agreement; Serono will use them to develop drugs to diagnose and treat Alzheimer's disease and other neurodegenerative diseases; Axonyx will receive an initial payment of $1.5M and future payments of up to $21M, as well as potential royalties (10/23) |
Bioject Medical Technologies Inc. (BJCT) | Serono SA (Switzerland; NYSE:SRA) | Expanded licensing agreement for Vitajet3 system | Agreement expands Serono's rights to the Vitajet3 system to cover exclusive worldwide usage for all current and future growth hormone products and indications, including Saizen and Serostim; Serono also gains exclusive options to use all new technologies developed by Bioject in the delivery of growth hormone and has paid an undisclosed licensing fee to Bioject; further terms were ND (10/16) |
Biolog Inc.* | Paradigm Genetics (PDGM) | Licensing agreement for Biolog's Phenotype MicroArray technology | Paradigm will use the technology to determine gene function in agriculturally important fungal species; during the multi-year agreement, Paradigm will have non-exclusive rights to use the products (9/25) |
BioStar Inc.* | Agouron Pharmaceuticals Inc. (A Pfizer Inc. company; NYSE:PFE) | Amended agreement for BioStar's technology | Biostar granted Agouron a non-exclusive license, within a specified field of use, for BioStar's patented technology for optical detection of nucleic acids (9/26) |
British Biotech plc (UK; LSE:BBG;BBIOY) | Serono SA (Switzerland;NYSE:SRA) | Exclusive research, development and commercialization agreement | Serono and British Biotech will jointly research, develop and commercialize metalloenzyme inhibitors to treat serious inflammatory diseases; British Biotech will receive an initial payment of US$5M, a series of undisclosed milestone payments and eventual royalties; the companies will share the research costs equally; Serono will cover product development costs, but British Biotech has the right to fund half of such costs and may co-promote products with Serono; cash payments and research funding to British Biotech could total between US$30M and US$80M (10/17) |
Celera Genomics (NYSE:CRA) | ValiGen N.V.* | Five-year genomics agreement for a subscription to Celera's database products | ValiGen will receive a subscription to all of Celera's database products, bioinformatics systems and other discovery tools; financial terms were ND (9/28) |
Clingenix Inc.* | MJ Life Co.* (Taiwan) | Collaboration for new technologies | MJ Life will provide its laboratory services and expertise to Clingenix's pharmacogenomics capabilities and will provide samples and database information from clinical trials throughout Asia; MJ Life will have the first right of refusal to market in Asia all new methods and technologies that Clingenix develops in the collaboration; companies will share revenues; financial terms were ND (9/11) |
Connetics Corp. (CNCT) | Alza Corp.** (NYSE:AZA) | Agreement to develop an advanced drug delivery system | Companies will develop a system for Connetics' recombinant human relaxin drug candidate, focusing on Alza's implantable drug delivery technology, or DUROS system; Connectics will pay all development costs and make milestone payments and royalties (10/3) |
Coulter Pharmaceutical Inc. (CLTR) | Cobra Therapeutics Ltd.* (gene therapy subsidiary of ML Laboratories;UK) | Collaboration to jointly develop and commercializae Cobra's platform gene expression technology | The companies will jointly develop and commercialize the Ubiquitous Chromatin Opening Elements technology; Coulter will make an up-front payment of £1M and milestone and sublicense fees; any products commercialized after the first two will be subject to a royalty fee; the agreement also allows for sublicensing of the technology; revenues from third-party milestone and royalty payments will be split equally (10/3) |
CuraGen Corp. (CRGN) | Abgenix Inc. (ABGX) | Selection of 24 antibody drug targets in five-year strategic collaboration | The companies selected 24 antibody drug targets for further evaluation and possible development as cancer therapeutics; CuraGen and Abgenix are collaborating to identify and develop up to 120 antibody drug candidates against cancer, inflammation and autoimmune disease (8/15) |
CuraGen Corp. (CRGN) | Biogen Inc. (BGEN) | Licensing agreement for five drug targets | CuraGen licensed five drug targets to Biogen, marking the completion of the research portion of their discovery collaboration; CuraGen is entitled to receive potential milestone payments and royalty payments, as well as additional milestone and royalty payments for other discoveries stemming from the research collaboration (10/9) |
De Novo Pharmaceuticals Ltd. (UK)* | British Biotech (UK; LSE:BBG) | Discovery agreement/British Biotech's existing in-house research in antibacterial drug discovery will be enhanced | British Biotech has made an initial payment and will provide research funding for a period of 12 months; De Novo will apply itsplatform of computer algorithms to provide novel, small-molecule leads for British Biotech to exploit in its research; financial terms were ND (8/00) |
Discovery Partners International Inc. (DPII) | Maxia Pharmaceuticals Inc.* | Collaboration to design and synthesize compounds that may have utility in Maxia's research and development programs | Maxia will have exclusive rights to develop and commercialize resulting compounds; financial terms were ND (10/11) |
Discovery Partners International Inc. (DPII) | Procter & Gamble Pharmaceuticals (NYSE:PG)** | Multi-year agreement to provide purified, diverse compounds for pharmaceutical screening | ChemRx Advanced Technologies will provide Procter & Gamble with compounds over three years, with the option of also providing hit follow-up and lead optimization; ChemRx is a division of DPII; financial terms were ND (10/2) |
Diversa Corp. (DVSA) | Arctos Pharmaceuticals Inc.* | Biodiversity access/Diversa gains rights to discover genes and and commercialize products from samples extracted from habitats in Alaska and neighboring territories | Diversa will support sample collection efforts and pay royalties on Diversa's revenues from any products developed from samples provided; Diversa gains access to environments covered by agreements Arctos has signed over the past five years with Alaskan landholding native corporations, individuals and other entities (8/00) |
DNAPrint Genomics Inc. (Pink Sheets: DNAP) | Geospiza Inc.* | License agreement for beta-testing of Geospiza's DNA sequence information management system |
DNAPrint will use and test the system, called Finch-Server (8/4) |
DNAPrint Genomics Inc. (Pink Sheets; DNAP) | Orchid BioSciences Inc. (ORCH) | Option agreement to co-develop and co-commercialize certain intellectual properties and products of DNAPrint Genomics | DNAPrint grants Orchid an option to license exclusive rights to genetic algorithms, software and information resources, such assingle nucleotide polymorphism and haplo-type determinations and multivariate associations with complex human traits and diseases; other terms were ND (10/24) |
Dyax Corp. (DYAX) | Unilever Nederland B.V.* (the Netherlands) | Licensing agreement for patents covering yeast display technology | Dyax acquired from Unilever worldwide patent rights covering yeast display technology, with exclusive rights in the field of therapeutics; Unilever gains access to Dyax's phage display patents for selected applications (9/13) |
Ecopia Biosciences* (Canada) | Kosan BioSciences* | Collaborative research and license agreement | Ecopia will apply its genomics platform in order to discover the genes responsible for directing the synthesis of a small molecule, which is of interest to Kosan, and that is naturally produced by an environmental microorganism; financial terms of the six-month agreement were ND (10/19) |
EntreMed Inc. (ENMD) | Chiron Corp. (CHIR) | Manufacturing agreement for Endostatin | Chiron will continue production of bulk Endostatin protein for Phase II trials (10/11) |
Eos Biotechnology Inc.* | Biogen Inc. (BGEN) | Multi-year research and development collaboration to identify targets for antibody and protein therapeutics in the area of breast cancer | The value of the collaboration to Eos could reach $55M, not including royalties; the agreement also includes an option for Eos to produce fully human therapeutic anti-bodies against validated targets identified in the collaboration; in return for providing Biogen with exclusive worldwide rights to breast cancer-specific molecules for use in the development of new therapeutics, Eos will receive an up-front payment, research funding and milestone and royalty payments on resulting products; Biogen also has made a $5M equity investment in Eos (9/13) |
Epoch Biosciences (EBIO) | Applied Biosystems Group (NYSE:PEB) | Expanded relationship from a limited licensing agreement to a strategic alliance to incorporate Epoch's technology in the entire line of Applied's TagMan reagent products | Applied's TagMan probes will feature Epoch's minor groove binder technology; Applied will market the new probes and will fund research and pay supplemental license fees; other financial terms were ND (8/18) |
Gemini Genomics plc (UK;GMNI) |
CuraGen Corp. (CRGN) | Drug target discovery collaboration | Companies will apply CuraGen's PathCalling proteomic technology for ascertaining the biological context of disease-associated genes; the parties will jointly own intellectual property arising from the collaboration; they will commercialize the results by licensing the rights to discoveries (10/10) |
GeneData AG* (Switzerland) | Altana AG* (Germany) | Multi-year alliance to establish new molecular approaches to drug research on the basis of computer-assisted analysis of functional genomics data | GeneData will provide access to its bio-informatics platform and will assist Altana's pharmaceutical group, Byk Gulden, in the analysis of functional genomics data (8/30) |
Gene Logic Inc. (GLGC) | Amersham Pharmacia Biotech K.K. (Japanese subsidiary of Amersham Pharmacia Biotech Ltd.) | Alliance for distribution and marketing rights | Agreement grants Amersham exclusive distribution rights to market and sell Gene Logic's products to the Japanese market; Amersham will become the primary sales and marketing vehicle for Gene Logic's products in Japan; financial terms were ND (9/26) |
Genencor International Inc. (GCOR) | Medarex Inc. (MEDX) | Expanded scope of licenses from Medarex | Genencor will develop, generate and use mice with transplanted human cells for research and development of commercial non-antibody therapeutic products (8/22) |
Genencor International Inc. (GCOR) | Xgene Corp.* | Expanded research collaboration | Companies will collaborate for an additional two years to develop tools to test compounds for activity against the human papilloma virus and test the efficacy of compounds in human skin inflammation; Xgene will complete development of an in vitro skin equivalent useful for testing in Genencor's com-pounds and will develop a second in vitro assay useful for testing the efficacy in dermatological disorders; Genencor will fund Xgene's research activities for the development of the tools and will receive exclusive rights to use the assays developed under the agreement (9/19) |
Gene Tec Corp.* | Applied Biosystems Group (NYSE:PEB) | Non-exclusive license agreement | Gene Tec granted Applied Biosystems a non-exclusive license to its patented method of amplifying nucleic acid targets directly in cells and viruses (8/9) |
|
Geneva Proteomics Inc.* (Switzerland) | Bruker Daltonics Inc. (BDAL) | Strategic alliance agreement in proteomics | Geneva Proteomics purchased 51 mass spectrometry systems, as well as consumables and support from Bruker; Bruker is making a strategic equity investment, in cash and stock, in Geneva Proteomics (9/12) |
Genometrix Inc.* | Genomics Collaborative Inc.* | Research collaboration to analzye DNA samples for profiling single nucleotide polymorphisms (SNPs) | The study will focus on hypertension and is designed to enable researchers to discover correlations between genetic variation and disease risk, toxicity assessments and drug response (8/10) |
Genomica Corp.* | Genome Therapeutics Corp. (GENE) | Software licensing agreement | Genomica licensed its Discovery Manager software to Genome Therapeutics; financial terms were ND (9/27) |
Genomics Collaborative Inc.* | PolyGenyx* | Research collaboration for discovering correlations between genetic variation and disease risk | Collaboration will apply PolyGenyx's high-throughput HaploScan technology to single nucleotide polymorphism haplotyping; study will focus on coronary artery disease; financial terms were ND (9/14) |
Genomic Solutions Inc. (GNSL) | Research Genetics (a unit of Invitrogen Corp.; IVGN) | Non-exclusive agreement in which Research Genetics will supply PCR product to Genomic Solutions for printing on Gene-Map microarrays | The libraries provided by Research Genetics consist of more than 40,000 human genes, 17,500 rat genes and 5,000 mouse genes; agreement also covers any libraries that Research Genetics offers in the future (10/18) |
Genomic Solutions Inc. (GNSL) | Unnamed mass spectrometer companies | Collaboration for designing its Investigator Proteomic System | Genomic Solutions is collaborating with mass spectrometers from major manufacturers to design its Investigator Proteomic System (10/6) |
Genta Inc. (GNTA) | Oasis Biosciences Inc.* | Non-exclusive license agreement for antisense patents | Agreement includes up-front payments in cash and royalties on product sales; Genta retains rights to the patents for its own use, as well as an exclusive right to grant unrestricted sublicenses to other users (9/28) |
Genzyme General (GENZ) | Cambridge Antibody Technology (UK; LSE:CAT) | Strategic alliance to develop and commercialize human monoclonal antibodies directed against TGF-b | Companies will initially focus on developing a fully human monoclonal antibody-based treatment for scleroderma; Genzyme received an exclusive worldwide license to Cambridge's fully human antibodies directed against TGF-b for all uses excluding ophthalmology; Genzyme also has received a non-exclusive worldwide license for non-antibody antagonists of TGF-b in exchange for milestones and royalties; research, development and commercialization activities will be funded jointly and the partners will share profits; Genzyme will make a $20M equity investment in Cambridge (9/28) |
Genzyme Molecular Oncology (GZMO) | Celera Genomics (NYSE:CRA) | Co-exclusive worldwide marketing agreement for the SAGE database | Genzyme granted Celera rights to market the SAGE (serial analysis of gene expression) database to Celera customers; Genzyme will license the database on a revenue-sharing basis; further details were ND (9/25) |
Genzyme Molecular Oncology (GZMO) | Invitrogen Corp. (IVGN) | Exclusive worldwide licensing agreement for SAGE | Genzyme and Invitrogen signed a licensing agreement granting Invitrogen exclusive worldwide rights to sell SAGE (serial analysis of gene expression) genomics technology in standardized reagent kits; Genzyme will receive an up-front payment and royalties on sales of each kit (10/10) |
Genzyme Molecular Oncology (GZMO) | Myriad Genetics Inc. (MYGN) | Licensing agreement for Genzyme's cancer diagnostic patent rights related to an undisclosed gene implicated in hereditary colon cancer | Genzyme received an up-front payment and will receive royalties on each Colaris test performed; further financial details were ND (8/24) |
Genzyme Molecular Oncology (GZMO) | NeuralStem Biopharmaceuticals Ltd.* | License agreement for SAGE genomics technology | NeuralStem will use SAGE (serial analysis of gene expression) genomics technology for evaluation of global gene expression from its human central nervous system stem cells; Genzyme will receive an up-front payment and additional fees related to the creation of SAGE data and upon the transfer of data to third parties; NeuralStem may extend the license for up to five years (7/31) |
Genzyme Transgenics Corp. (GZTC) | Sumitomo Metals Industries Ltd.* | Dissolved 10-year-old joint venture | Genzyme re-acquired its rights to technology for the production of medicines from milk in 18 Asian countries, including Japan; the rights were re-acquired for 333,334 shares of Genzyme's stock, worth about $11.8M (10/2) |
HTS Biosystems Inc.* | Boston Probes Inc.* and Applied Biosystems (NYSE:PEB) | Licensing agreement for PNA technology | HTS received a combined license from Boston Probes and Applied Biosystems for the use of peptide nucleic acid technology in the field of proteomics; HTS will pay Boston Probes an up-front fee, maintenance fees and royalties from product sales (10/10) |
ICAgen Inc.* | NPS Allelix (Canada; unit of NPS Pharmaceuticals Inc.; NPSP) | License agreement for nervous system-specific sodium channel gene technology | ICAgen obtained a sole license for the technology and obtained exclusive rights to storeor receptor-operated calcium channels from the University of California, Los Angeles (8/2) |
ICOS Corp. (ICOS) | Array BioPharma (ARRY) | Expanded drug discovery collaboration; process research and manufacturing agreement | ICOS has exclusive worldwide rights to develop and market any products resulting from the collaboration; ICOS will provide funding and make milestone payments for the development and commercialization of resulting products (8/3) |
ImClone Systems Inc. (IMCL) | Lonza Biologics* (unit of Lonza Group Ltd.; Switzerland) | Manufacturing agreement for ImClone's lead cancer therapeutic, IMC-C225 | The agreement calls for Lonza to be a second source manufacturer of IMC-C225 (9/7) |
Incyte Genomics Inc. (INCY) | NEN Life Science Products (a unit of Perkin-Elmer Inc.; NYSE: PKI) | Licensing agreement for cDNA clone collection from LifeSeq Gold | NEN will gain access to Incyte's collection of cDNA clones from LifeSeq Gold for the commercialization of microarrays; Incyte will receive royalties on sales; financial terms were ND (10/4) |
Incyte Genomics Inc. (INCY) | Sequenom Inc. (SQNM) | Collaboration to create SNP assays for use in genetics research | Companies will work together to create single nucleotide polymorphism assays; Incyte will license SNPs to Sequenom, which will provide Incyte with access to the Mass-array technology and validation strategies; financial terms were ND (10/2) |
InforMax Inc. (INMX) | Structural Bioinformatics Inc.* | Distribution agreement for SBI's database content of atomic resolution 3-D protein models | The database will be offered to GenoMax customers (9/12) |
Interferon Sciences Inc. (OTC BB:IFSC) | Metacine Inc.* | Option to purchase about 50% of Metacine's common stock | An independ third party will conduct a review and analysis of Metacine's intellectual property, under terms of the agreement; the option was acquired for $100,000 and may be exercised during the 60-day period following ISI's receipt of the review; if exercised, Metacine will issue 43% of its common stock to ISI, which also will receive a warrant to purchase additional shares for up to 5 years (10/17) |
Incyte Genomics Inc. (INCY) | Elitra Pharmaceuticals Inc. (ELIT) | Antimicrobial genomics collaboration | Incyte will provide Elitra an exclusive license to Incyte's PathoSeq microbial sequence database technologies and Elitra will obtain the right to market and sell the database to third parties; Incyte will receive equity in Elitra (7/00) |
InterMune Pharmaceuticals Inc. (ITMN) | Genentech Inc. (NYSE:DNA) | License agreement/InterMune received exclusive rights to commercialize Actimmune in Japan for treatment and prevention of chronic granulomatous disease or osteopetrosis | Genentech will receive royalty payments on all sales in Japan; prior to obtaining these additional commercialization rights, Inter-Mune had exclusive rights to commercialize this product in Japan for infectious tuberculosis (8/00) |
KS Biomedix Holdings plc (UK; LSE:KSB.L) |
Eukarion Inc.* |
Research and development collaboration for Eukarion's antibody lipidation and chemical modification technologies |
The technologies could enable KSB's sheep monoclonal antibodies to be exploited against novel disease targets (8/23) |
Large Scale Biology Corp. (LSBC) |
Dow** AgroSciences LLC (unit of Dow Chemical Co.; NYSE:DOW) |
Completion of a strategic collaboration milestone |
Large Scale announced that it completed the fifth milestone in the strategic collaboration by delivering to Dow a fully, functional, metabolic pathway database; total funding to date exceeds US$45M over the first two years of the three-year agreement (9/26) |
Lexicon Genetics Inc. (LEXG) |
Affymetrix Inc. (AFFX) |
Supply agreement for GeneChip technology |
Lexicon will obtain GeneChip technology for its internal drug discovery program, initially applying it to its oncology program (9/14) |
Lexicon Genetics Inc. (LEXG) |
Biogen Inc. (BGEN) |
Non-exclusive sublicense for Lexicon's positive-negative selection technology for the generation of knockout mice |
Biogen will use the technology in its internal drug discovery and target validation programs; financial terms were ND (9/6) |
Lexicon Genetics Inc. (LEXG) |
Tularik Inc. (TLRK) |
Multi-year functional genomics research agreement |
Tularik will have access to conditional knockouts and gene-specific knockouts, generated using Lexicon's gene targeting program, with genetic alterations directed at specific drug targets selected by Tularik; Tularik also will have access to the OmniBank library of knockout mouse clones; financial terms were ND (10/5) |
Lorus Therapeutics Inc. (Canada; TSE:LOR; LORFF) |
Proligo (a joint venture between SKW Trostberg AG and Gilead Sciences Inc.; GILD) |
Strategic supply alliance |
Lorus entered into an alliance with Proligo, which will invest in resources to increase the capacity of the production process for GTI-2040 to supply the product for Phase II trials (10/17) |
Luminex Corp. (LMNX) |
Life Technologies Inc. (OTC BB:LTEK.OB) |
Multi-year strategic partnership for reagents and instrumentation based on Luminex's LabMAP technology |
Life was granted worldwide non-exclusive rights to develop and distribute reagents and instrumentation; Luminex received an up-front payment and will receive future royalties on potential products (8/16) |
Luminex Corp. (LMNX) |
Upstate Biotechnology* |
Strategic partnership to develop reagents and assay kits |
Companies will develop the reagents and assay kits for basic research and drug discovery applications based on Luminex's LabMAP technology (10/5) |
Lynx Therapeutics Inc. (LYNX) |
Genomics Collaborative Inc.* |
Strategic corporate partnership to identify a comprehensive set of diabetes-associated SNPs |
Scientists from both companies designed a study to conduct a genome-wide scan for single nucleotide polymorphisms (SNPs) associated with Type II diabetes; financial terms were ND (8/16) |
Lynx Therapeutics Inc. (LYNX) |
Molecular Engines Laboratories SA (Paris)* |
Two-year research collaboration to identify differentially expressed genes associated with tumor reversion |
Lynx will apply its Megasort technology to cancer cell lines provided by MEL; Lynx also will receive payments for genomic discovery services, and royalty payments; other financial terms ND (10/17) |
Maxygen (MAXY) |
Chevron Research and Technology Co. |
Three-year agreement to develop novel bioprocesses for specific petrochemical products |
Chevron will have commercialization rights in exchange for license fees, technology access fees, full research funding, milestones, annual fees and product royalties (10/25) |
Medarex Inc. (MEDX) |
Athersys Inc.* |
Collaboration to developtherapeutics produced through the joint application of the HuMAb-mouse technology and Athersys' RAGE technology |
Companies plan to jointly discover, develop and commercialize fully human antibodies as therapeutics for cancer and other diseases; Athersys acquired an option to obtain access to Medarex's technology for targets outside the collaboration; Medarex acquired an option to obtain access to validated therapeutic targets produced with RAGE-VT technology and also has made an equity investment in Athersys (8/16) |
Medarex Inc. (MEDX) |
Immuno-Designed Molecules SA* (France) |
Definitive agreement whereby IDM acquired rights to certain Medarex products and technology |
IDM acquired worldwide rights to use Medarex's MDX-210 anti-HER2 product in connection with cell therapy, as well as MDX-220 and MDX-447 in all fields; Medarex increased its ownership interest in IDM from 6% to about 34%; the definitive agreement supercedes the agreement announced in February; IDM will not acquire rights to MDX-33, MDX-22 and certain Medarex research programs (10/23) |
Medarex Inc. (MEDX) |
Oxford GlycoSciences plc (UK; LSE:OGS) |
Alliance to develop therapeutics produced using Medarex's fully human monoclonal antibody technology and OGS's proteomics technology |
Companies will jointly discover, develop and commercialize fully human antibodies as therapeutics; they expect OGS to provide up to 30 protein targets for cancer or other life-threatening diseases; companies will share preclinical and clinical responsibilities, and intend to jointly commercialize resulting products; Medarex will make a $5M equity investment in OGS (9/11) |
Medarex Inc. (MEDX) |
ZymoGenetics Inc.* |
Alliance to develop fully human antibody products |
Companies will combine Medarex's fully human monoclonal antibody development technology and ZymoGenetics' expertise in the field of genomics and protein therapeutics to create antibodies to multiple disease products; ZymoGenetics is responsible for the development and commercialization of resulting products; Medarex expects to receive license fees and milestone payments, as well as royalties on potential sales (10/19) |
Morphochem AG (Germany) |
Synt:em Inc.* (France) |
Strategic alliance to discover and develop novel therapeutics |
Morphochem and Synt:em entered into a strategic alliance to discover, validate and develop products up to clinical trials with the initial focus to be on new antiviral compounds (10/17) |
MorphoSys AG (Germany; Neuer Markt: MOR) |
ImmunoGen Inc. (IMGN) |
Collaboration to develop human antibodies |
Two companies will collaborate on the development of human antibodies to treat cancer; MorphoSys will receive a technology access payment, as well as development-related milestone payments and royalties on marketed products; financial details were ND (10/2) |
Motorola Inc. (BioChip Systems unit;NYSE:MOT) |
Iconix Pharmaceuticals Inc. |
Strategic relationship to enable the creation of a next-generation chemical genomic database |
Iconix will validate the beta release of Motorola's new CodeLink Expression System in the multi-year agreement; Motorola has made an equity investment in Iconix and received rights to distribute the resulting Iconix ChemExpress database as part of future BioChip System solutions (8/10) |
Motorola Inc. NYSE:MOT) |
Incyte Genomics Inc. (INCY) |
Licensing agreement for the rights to Incyte's gene sequence databases and gene patent portfolio, including LifeSeq Gold human gene sequence database and ZooSeq animal gene sequence database |
Motorola has licensed Incyte's patented gene sequences to develop, manufacture and sell gene expression chips, or bioarrays; Motorola expects to commercialize DNA bioarrays; Incyte will receive royalties; financial terms were ND (8/17) |
Nanogen Inc. (NGEN) |
Hitachi Ltd., Nissei Sangyo Co. Ltd. and Hitachi Instruments Service Co. Ltd. (Japan) |
Long-term collaboration for the development, manufacturing and distribution of products based on Nanogen's and Hitachi's technologies |
The 10-year agreement provides the framework for a joint investment of about $57M in applications development funding; further investments could exceed $140M; Hitachi willmake an equity investment in Nanogen; Nanogen will assist customers using the NanoChip Molecular Biology Workstation in developing diagnostic markers and in extending the NanoChip system's application menu to include gene expression, integrated amplification and protein analysis; Hitachi will provide annual funding for general applications development (8/2) |
Nexell Therapeutics Inc. (NEXL) |
NeoRx Corp. (NERX) |
Exclusive license for 10 years for all in vitro diagnostic applications of the NRLU-5 antibody |
Nexell obtained the rights to NRLU-5; financial terms were ND (8/2) |
Northwest Biotherapeutics Inc.* |
Cytogen Corp. (CYTO) |
Exclusive worldwide agreement for the sublicense of prostate specific membrane antigen |
Agreement clarifies Northwest's right to make, have made, use and sublicense prostate specific membrane antigen, for ex vivo prostate cancer immunotherapy; terms were ND (8/30) |
Northwest Biotherapeutics Inc.* |
Protein Sciences Corp.* |
Kidney cancer target manufacturing contract |
Northwest selected Protein Sciences to develop a high-yield expression vector for production of a kidney cancer-specific protein as a component of a new treatment for renal cell carcinoma; terms were ND (10/16) |
NPS Allelix Corp. (Canada; unit of NPS Pharmaceuticals Inc.; NPSP) |
Forest Laboratories Inc. (NYSE:FRX) |
Agreement for the development and worldwide marketing of ALX-0646 to treat migraine headache |
No further details were disclosed (8/29) |
NsGene AS* (Denmark) |
Neurotech SA* (France) |
Collaboration and license agreements regarding the research and development of Neurotech's Encapsulated Cell Technology to treat neurological and eye disorders |
NsGene will focus its development efforts onECT products to treat neurodegenerative disorders and epilepsy, while Neurotech will focus on the treatment of diseases of the eye and cancer; NsGene paid Neurotech an undisclosed up-front fee and both parties will receive cross royalties on potential products (8/29) |
Oncotech Inc.* |
Beckman Coulter Inc. (NYSE:BEC) |
Strategic alliance to develop and commercialize gene expression technologies that can be used to diagnose cancer |
The companies will collaborate on discovery of new genetic markers for early stage malignancies in colon, ovarian, breast, prostate and lung cancers (8/22) |
Orchid BioSciences Inc. (ORCH) |
Tecan (Switzerland; SWX:TECN) |
Strategic partnership for the supply of systems solutions for DNA processing |
Tecan will supply Orchid with its automated DNA processing solution for use in the manufacture of SNPware consumable kits; financial terms were ND (9/18) |
Orchid BioSciences Inc. (ORCH) |
DNAPrint Genomics Inc. (Pink Sheets: DNAP) |
Purchasing agreement for Orchid's SNPstream 25K system |
DNAPrint agreed to purchase Orchid's SNPstream 25K system for single nucleotide polymorphism scoring; DNAPrint will make an up-front payment and will purchase SNP-ware consumables on a per-unit basis; other details were ND (10/6) |
Oxford BioMedica plc (UK; LSE:OXB) |
InforMax Inc. (INMX) |
Software licensing agreement |
Companies agreed to enter discussions about marketing jointly the genetic information produced from BioMedica's gene discovery programs; BioMedica will retain full commercial licensing rights to the genes themselves and the products derived from them (9/26) |
Oxford GlycoSciences (UK; LSE:OGS) | Packard BioScience Co. (PBSC) | Collaboration to develop protein biochips | Companies will apply their respective technologies to develop protein biochips (9/19) |
Oxford Molecular Group plc (UK; LSE:OMG) | Pharmocopeia Inc. (PCOP) | Definitive agreement to acquire OMG's software subsidiary | Pharmacopeia will acquire OMG's software business for $27M, comprised of cash and the assumption of certain liabilities (8/00) |
Oxford GlycoSciences (UK; LSE:OGS) | Packard BioScience Co. (PBSC) | Collaboration to develop protein biochips | Companies will apply their respective technologies to develop protein biochips (9/19) |
Oxford Molecular Group plc (UK; LSE:OMG) | Pharmocopeia Inc. (PCOP) | Definitive agreement to acquire OMG's software subsidiary | Pharmacopeia will acquire OMG's software business for $27M, comprised of cash and the assumption of certain liabilities (8/00) |
Packard BioScience Co. (PBSC) | Agencourt Bioscience Corp.* | Strategic marketing alliance | The two companies have agreed to co-market their respective products for nucleic acid purification; Packard purchased an equity stake of less than 10% in Agencourt (10/11) |
Phytera Inc.* | Novelos Therapeutics Inc.* | Development and commercialization agreement for BAM-002 | Phytera obtained exclusive North American rights to the cancer agent BAM-002, which is in Phase I/II trials; the two companies will collaborate on the development of the agent and related products; Phytera will be responsible for marketing and Novelos will be responsible for manufacturing; financial terms were ND (8/14) |
PolyMASC Pharmaceuticals plc (subsidiary of Valentis Inc.;VLTS) | Flemington Pharmaceutical Corp. (OTC BB:FLEM) | Research agreement/ companies will work to develop a formulation of PEGylated insulin delivered by Flemington's Immediate-Immediate Release lingual spray system | Each party will be responsible for its own development costs; if the feasibility studies are successful, the companies intend to seek a corporate partner to assist in the development and marketing of the product (8/00) |
PowderJect Pharmaceuticals plc (UK; LSE:PJP) | Aviron (AVIR) | Revised agreement for the manufacture of Aviron's FluMist | PowderJect said its subsidiary, Evans Vaccines Ltd., renegotiated the agreement; Aviron will make initial payments to PowderJect totaling $15M, with further payments of $4M per year for five years; PowderJect also will receive additional performance-based milestone payments of up to $3M (10/11) |
PPL Therapeutics (UK; LSE:PTH) | Undisclosed biotechnology company | Agreement to undertake a feasibility study for the transgenic production of a peptide that inhibits excess tissue formation | The companies will study the transgenic production, initially in the milk of rabbits, of the peptide; other details were ND (9/8) |
Procyon BioPharma Inc. (Canada; TSE:PBP) | Biovation Ltd.* (Scotland) | Agreement for the development of chimeric and de-immunized ANA therapeutic monoclonal antibodies | Companies signed a letter of intent for the agreement; the definitive agreement will spell out in greater detail the development plans, milestones, deliverables and contractual obligations (10/5) |
Prolinx Inc.* | Calbiochem-Novabiochem Corp. (unit of CN Bio-Sciences Inc.) | Non-exclusive, worldwide, co-label agreement for Prolinx's Versalinx Chemical Affinity Tools product line | Marketing rights granted are limited to research applications in the field of life science; Prolinx retains all rights to intellectual property and licensing for commercial applications for the Versalinx technology (9/11) |
Proteome Inc.* | Celera Genomics (NYSE:CRA) | Strategic collaboration to link Proteome's BioKnowledge library through the Celera Discovery System | Proteome will license the BioKnowledge Library to Celera for distribution with the Celera Discovery System (9/14) |
Proteome Systems Ltd.* (Australia) | Sigma-Aldrich (SIAL) | Manufacturing and exclusive distribution agreement | Sigma-Aldrich will exclusively manufacture and distribute certain products developed by Proteome Systems for use in proteomic analysis (10/25) |
Rigel Pharmaceuticals Inc. (RIGL) | Cytomation Inc.* | Collaboration to screen for new drugs and targets | Companies will pair Cytomation's ultra-high-speed live-cell analyzer and sorter with Rigel's retroviral and gene transfer techniques to screen molecules for new drugs and drug targets (9/00) |
Sangamo BioSciences Inc. (SGMO) | Exelixis Inc. (EXEL) and Artemis Pharmaceuticals GmbH *(Germany) | Collaboration to produce knock-out mice for functional gene validation | Collaboration will combine the companies' technologies (10/2) |
Sangamo BioSciences Inc. (SGMO) | Rosetta Inpharmatics Inc. (RSTA) | Joint research collaboration | The companies intend to apply their technologies in gene regulation and informational genomics to perform functional genomic studies on potential therapeutic targets; each company will fund its respective efforts (9/26) |
SignalGene Inc. (Canada; TSE:SGI) | CroMedica Prime Inc.* | Service agreement for genotyping services | SignalGene will use its pharmacogenomics platform for the genotyping of drugs metabolizing enzymes on samples collected by CroMedica Prime from clinical trial participants (10/3) |
Sequitur Inc.* | Vertex Pharmaceuticals Inc. (VRTX) | Licensing agreement for antisense functional genomics technology | Vertex will provide financial support for collaborative research to be performed at Sequitur, and Vertex will pay licensing fees (9/25) |
Targeted Genetics Corp. (TGEN) | Biogen Inc. (BGEN) | Definitive agreement to establish a major multi-product development and commercialization collaboration | The collaboration will replace and expand an agreement Biogen established in 1995 with Genovo, a privately-held company to be acquired by Targeted Genetics; Targeted Genetics will work on the development of up to four new gene therapy products for Biogen; in return for access to technologies and product development capabilities, Biogen will pay $8M in up-front payments, as well as ongoing research and development funding and milestone payments; the funding also includes a $10M line of credit to Targeted Genetics and a future $10M equity investment; total value could be $125M, not including manufacturing and royalty payments (8/9) |
Third Wave Technologies Inc. | Epoch Biosciences (EBIO) | Development, licensing and supply agreement | Epoch will develop, license and supply certain of its technologies for Third Wave's Invader operating system for genetic analysis; Epoch will provide access to fluorescent dye chemistries and will receive licensing payments and royalties on sales; Third Wave will fund certain development activities and will have the option to license Epoch's minor groove binder and modified base technologies (10/10) |
Transgene SA (France; TRGNY) | Mirus* | Research and license agreement to develop gene therapy products | Companies will use Mirus' muscle delivery technology to deliver Transgene's plasmid-based and adenoviral vectors to skeletal muscle; Transgene will fund a one-year research program and Mirus grants Transgene an option to license its technology over a five-year period (10/11) |
Trega Biosciences Inc. (TRGA) | GemStone Systems Inc.* | Licensing agreement for the GemStone/J e-business software | GemStone licensed its software to Trega for use in the web-based version of the iDEA predictive model for absorption (9/11) |
Trega Biosciences Inc. (TRGA) | PhycoGen Inc.* | Service agreement for Chem.Folio chemistry | Trega will provide its Chem.Folio chemistry services for PhycoGen's use in discovery programs that involve biological cell adhesion processes; Trega will receive up-front and milestone payments (10/4) |
Valentis Inc. (VLTS) | Eurogene Ltd. (UK)* | Collaboration to develop a nitric oxide synthase gene medicine for the prevention or treatment of restenosis following bypass graft surgery | Valentis and Eurogene will share research and development costs and potential revenues (8/14) |
Valentis Inc. (VLTS) | Heska Corp. (HSKA) | Licensing agreement for gene delivery and DNA manufacturing technology | Heska will use the technology to complete development of a gene medicine to treat canine cancer; agreement includes up-front license fee, milestone payments and a royalty (10/23) |
Viragen Inc. (AMEX:VRA) | PolyMASC Pharmaceuticals plc (unit of Valentis Inc.; VLTS) | Collaboration to develop a new treatment for hepatitis C | Companies will use PolyMASC's protoMASC PEGylation process to deliver Viragen's lead drug, Omniferon; financial terms were ND (9/19) |
Viragen Inc. (AMEX:VRA) | Zonagen Inc. (ZONA) | Supply agreement for purpose of a study for genital herpes | Viragen agreed to supply Omniferon to Zonagen to study a topically applied enhanced formulation of natural alpha interferon for the treatment of genital herpes (8/29) |
Waratah Pharmaceuticals Inc. (Canada; CDNX:WAR) | Research Corp. Technologies* | License agreement for the use of RCT's protein expression system to produce Waratah's therapeutic proteins | Waratah will pay RCT royalties on net sales, including minimum annual royalties; terms were ND (10/24) |
Xenogen Corp.* | Cubist Pharmaceuticals Inc. (CBST) | Evaluation licensing agreement | Agreement provides Cubist with access to Xenogen's real-time, in vivo imaging technologies (8/24) |
XTL Biopharmaceuticals Ltd.* (Israel) | Hybrigenics SA* (France) | Agreement to co-develop drugs against hepatitis C virus | Agreement combines Hybrigenics' functional proteomics and bioinformatics drug discovery integrated platform with XTL's in vitro and in vivo predictive models of human HCV; both firms will share in the research and development costs associated with the program; each party will retain an equal interest in products developed and will jointly fund development through Phase II trials; Hybrigenics also granted XTL a non-exclusive license to HCV PIMRider technology database (9/4) |
Notes: | |||
# This chart does not include agreements that involve agricultural product development. | |||
* Private companies are indicated with an asterisk. **Denotes a pharmaceutical company. ND = not disclosed. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AMEX =American Stock Exchange; NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange; SWX = Switzerland Stock Exchange TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange | |||
